The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors

L. Zhou*, J. Lyons-Rimmer, S. Ammoun, J. Müller, E. Lasonder, V. Sharma, E. Ercolano, D. Hilton, I. Taiwo, M. Barczyk, C.O. Hanemann

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Merlin has broad tumor-suppressor functions as its mutations have been identified in multiple benign tumors and malignant cancers. In all schwannomas, the majority of meningiomas and 1/3 of ependymomas Merlin loss is causative. In neurofibromatosis type 2, a dominantly inherited tumor disease because of the loss of Merlin, patients suffer from multiple nervous system tumors and die on average around age 40. Chemotherapy is not effective and tumor localization and multiplicity make surgery and radiosurgery challenging and morbidity is often considerable. Thus, a new therapeutic approach is needed for these tumors. Using a primary human in vitro model for Merlin-deficient tumors, we report that the Ras/Raf/mitogen-activated protein, extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) scaffold, kinase suppressor of Ras 1 (KSR1), has a vital role in promoting schwannomas development. We show that KSR1 overexpression is involved in many pathological phenotypes caused by Merlin loss, namely multipolar morphology, enhanced cell-matrix adhesion, focal adhesion and, most importantly, increased proliferation and survival. Our data demonstrate that KSR1 has a wider role than MEK1/2 in the development of schwannomas because adhesion is more dependent on KSR1 than MEK1/2. Immunoprecipitation analysis reveals that KSR1 is a novel binding partner of Merlin, which suppresses KSR1's function by inhibiting the binding between KSR1 and c-Raf. Our proteomic analysis also demonstrates that KSR1 interacts with several Merlin downstream effectors, including E3 ubiquitin ligase CRL4DCAF1. Further functional studies suggests that KSR1 and DCAF1 may co-operate to regulate schwannomas formation. Taken together, these findings suggest that KSR1 serves as a potential therapeutic target for Merlin-deficient tumors.

Original languageEnglish
Pages (from-to)3443-3453
Number of pages11
JournalOncogene
Volume35
Issue number26
Early online date9 Nov 2015
DOIs
Publication statusPublished - 30 Jun 2016

Fingerprint

Neurofibromin 2
Protein Kinases
Neurilemmoma
Neoplasms
Therapeutics
Extracellular Signal-Regulated MAP Kinases
Cell-Matrix Junctions
Nervous System Neoplasms
Neurofibromatosis 2
MAP Kinase Kinase Kinases
KSR-1 protein kinase
Ependymoma
Focal Adhesions
Ubiquitin-Protein Ligases
Radiosurgery
Meningioma
Mitogens
Immunoprecipitation
Proteomics

Cite this

Zhou, L., Lyons-Rimmer, J., Ammoun, S., Müller, J., Lasonder, E., Sharma, V., ... Hanemann, C. O. (2016). The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors. Oncogene, 35(26), 3443-3453. https://doi.org/10.1038/onc.2015.404
Zhou, L. ; Lyons-Rimmer, J. ; Ammoun, S. ; Müller, J. ; Lasonder, E. ; Sharma, V. ; Ercolano, E. ; Hilton, D. ; Taiwo, I. ; Barczyk, M. ; Hanemann, C.O. / The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors. In: Oncogene. 2016 ; Vol. 35, No. 26. pp. 3443-3453.
@article{b6204a90948f4715924201ff2f8a946f,
title = "The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors",
abstract = "Merlin has broad tumor-suppressor functions as its mutations have been identified in multiple benign tumors and malignant cancers. In all schwannomas, the majority of meningiomas and 1/3 of ependymomas Merlin loss is causative. In neurofibromatosis type 2, a dominantly inherited tumor disease because of the loss of Merlin, patients suffer from multiple nervous system tumors and die on average around age 40. Chemotherapy is not effective and tumor localization and multiplicity make surgery and radiosurgery challenging and morbidity is often considerable. Thus, a new therapeutic approach is needed for these tumors. Using a primary human in vitro model for Merlin-deficient tumors, we report that the Ras/Raf/mitogen-activated protein, extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) scaffold, kinase suppressor of Ras 1 (KSR1), has a vital role in promoting schwannomas development. We show that KSR1 overexpression is involved in many pathological phenotypes caused by Merlin loss, namely multipolar morphology, enhanced cell-matrix adhesion, focal adhesion and, most importantly, increased proliferation and survival. Our data demonstrate that KSR1 has a wider role than MEK1/2 in the development of schwannomas because adhesion is more dependent on KSR1 than MEK1/2. Immunoprecipitation analysis reveals that KSR1 is a novel binding partner of Merlin, which suppresses KSR1's function by inhibiting the binding between KSR1 and c-Raf. Our proteomic analysis also demonstrates that KSR1 interacts with several Merlin downstream effectors, including E3 ubiquitin ligase CRL4DCAF1. Further functional studies suggests that KSR1 and DCAF1 may co-operate to regulate schwannomas formation. Taken together, these findings suggest that KSR1 serves as a potential therapeutic target for Merlin-deficient tumors.",
author = "L. Zhou and J. Lyons-Rimmer and S. Ammoun and J. M{\"u}ller and E. Lasonder and V. Sharma and E. Ercolano and D. Hilton and I. Taiwo and M. Barczyk and C.O. Hanemann",
year = "2016",
month = "6",
day = "30",
doi = "10.1038/onc.2015.404",
language = "English",
volume = "35",
pages = "3443--3453",
number = "26",

}

Zhou, L, Lyons-Rimmer, J, Ammoun, S, Müller, J, Lasonder, E, Sharma, V, Ercolano, E, Hilton, D, Taiwo, I, Barczyk, M & Hanemann, CO 2016, 'The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors', Oncogene, vol. 35, no. 26, pp. 3443-3453. https://doi.org/10.1038/onc.2015.404

The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors. / Zhou, L.; Lyons-Rimmer, J.; Ammoun, S.; Müller, J.; Lasonder, E.; Sharma, V.; Ercolano, E.; Hilton, D.; Taiwo, I.; Barczyk, M.; Hanemann, C.O.

In: Oncogene, Vol. 35, No. 26, 30.06.2016, p. 3443-3453.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors

AU - Zhou, L.

AU - Lyons-Rimmer, J.

AU - Ammoun, S.

AU - Müller, J.

AU - Lasonder, E.

AU - Sharma, V.

AU - Ercolano, E.

AU - Hilton, D.

AU - Taiwo, I.

AU - Barczyk, M.

AU - Hanemann, C.O.

PY - 2016/6/30

Y1 - 2016/6/30

N2 - Merlin has broad tumor-suppressor functions as its mutations have been identified in multiple benign tumors and malignant cancers. In all schwannomas, the majority of meningiomas and 1/3 of ependymomas Merlin loss is causative. In neurofibromatosis type 2, a dominantly inherited tumor disease because of the loss of Merlin, patients suffer from multiple nervous system tumors and die on average around age 40. Chemotherapy is not effective and tumor localization and multiplicity make surgery and radiosurgery challenging and morbidity is often considerable. Thus, a new therapeutic approach is needed for these tumors. Using a primary human in vitro model for Merlin-deficient tumors, we report that the Ras/Raf/mitogen-activated protein, extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) scaffold, kinase suppressor of Ras 1 (KSR1), has a vital role in promoting schwannomas development. We show that KSR1 overexpression is involved in many pathological phenotypes caused by Merlin loss, namely multipolar morphology, enhanced cell-matrix adhesion, focal adhesion and, most importantly, increased proliferation and survival. Our data demonstrate that KSR1 has a wider role than MEK1/2 in the development of schwannomas because adhesion is more dependent on KSR1 than MEK1/2. Immunoprecipitation analysis reveals that KSR1 is a novel binding partner of Merlin, which suppresses KSR1's function by inhibiting the binding between KSR1 and c-Raf. Our proteomic analysis also demonstrates that KSR1 interacts with several Merlin downstream effectors, including E3 ubiquitin ligase CRL4DCAF1. Further functional studies suggests that KSR1 and DCAF1 may co-operate to regulate schwannomas formation. Taken together, these findings suggest that KSR1 serves as a potential therapeutic target for Merlin-deficient tumors.

AB - Merlin has broad tumor-suppressor functions as its mutations have been identified in multiple benign tumors and malignant cancers. In all schwannomas, the majority of meningiomas and 1/3 of ependymomas Merlin loss is causative. In neurofibromatosis type 2, a dominantly inherited tumor disease because of the loss of Merlin, patients suffer from multiple nervous system tumors and die on average around age 40. Chemotherapy is not effective and tumor localization and multiplicity make surgery and radiosurgery challenging and morbidity is often considerable. Thus, a new therapeutic approach is needed for these tumors. Using a primary human in vitro model for Merlin-deficient tumors, we report that the Ras/Raf/mitogen-activated protein, extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) scaffold, kinase suppressor of Ras 1 (KSR1), has a vital role in promoting schwannomas development. We show that KSR1 overexpression is involved in many pathological phenotypes caused by Merlin loss, namely multipolar morphology, enhanced cell-matrix adhesion, focal adhesion and, most importantly, increased proliferation and survival. Our data demonstrate that KSR1 has a wider role than MEK1/2 in the development of schwannomas because adhesion is more dependent on KSR1 than MEK1/2. Immunoprecipitation analysis reveals that KSR1 is a novel binding partner of Merlin, which suppresses KSR1's function by inhibiting the binding between KSR1 and c-Raf. Our proteomic analysis also demonstrates that KSR1 interacts with several Merlin downstream effectors, including E3 ubiquitin ligase CRL4DCAF1. Further functional studies suggests that KSR1 and DCAF1 may co-operate to regulate schwannomas formation. Taken together, these findings suggest that KSR1 serves as a potential therapeutic target for Merlin-deficient tumors.

UR - http://www.scopus.com/inward/record.url?scp=84976905656&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.404

DO - 10.1038/onc.2015.404

M3 - Article

C2 - 26549023

VL - 35

SP - 3443

EP - 3453

IS - 26

ER -

Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V et al. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors. Oncogene. 2016 Jun 30;35(26):3443-3453. https://doi.org/10.1038/onc.2015.404